Reduced Intensity Conditioning (RIC) and Allogeneic Stem Cell Transplantation (AlloSCT) from
family-related donors and unrelated cord blood (UCB) donors will be safe and well tolerated
in selected patients with RDEB.
To determine the event-free survival (EFS) and overall survival (OS) following RIC consisting
of busulfan/fludarabine/alemtuzumab (BFA) and AlloSCT in selected patients with RDEB.